S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Renalytix Share Forecast, Price & News

GBX 117.50
+12.50 (+11.90%)
(As of 07/4/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
111,905 shs
Average Volume
130,779 shs
Market Capitalization
£87.84 million
P/E Ratio
Dividend Yield
Price Target

Renalytix MarketRank™ Forecast

Analyst Rating
Short Interest
Dividend Strength
News Sentiment
1.21mentions of Renalytix in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.58 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive RENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter.

Renalytix logo

About Renalytix (LON:RENX) Stock

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

RENX Stock News Headlines

The Renalytix share price – where next?
Renalytix announces a $30.0 million financing package
Fragrant Prosperity slumps as reverse takeover falls through
Renalytix Plc Share Chat
3 High-Growth Healthcare Stocks to Buy in September
Renalytix PLC - Price Monitoring Extension
Jersey Oil letting go of two licences
See More Headlines

Industry, Sector and Symbol

Diagnostics & Research
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
£2.42 million
Cash Flow
GBX 72.63 per share
Book Value
GBX 99.10 per share


Free Float
Market Cap
£87.84 million
Not Optionable

Renalytix Frequently Asked Questions

How has Renalytix's stock performed in 2022?

Renalytix's stock was trading at GBX 620 at the beginning of 2022. Since then, RENX stock has decreased by 81.0% and is now trading at GBX 117.50.
View the best growth stocks for 2022 here

Who are Renalytix's key executives?

Renalytix's management team includes the following people:
  • Mr. James R. McCullough M.B.A., CEO & Exec. Director (Age 54, Pay $1.13M)
  • Mr. Fergus Fleming, CTO & Exec. Director (Age 55, Pay $587k)
  • Mr. Thomas H. McLain CPA, M.B.A, Pres (Age 63)
  • Mr. Oliver James Sterling III, Chief Financial Officer
  • Ms. Andria Parks-Herrera, VP of Marketing
  • Ms. Jean M. Casner, Sr. VP & Chief HR Officer (Age 63)
  • Mr. Baljit Singh, Head of Clinical Operations
  • Dr. Michael J. Donovan M.D., Ph.D., Chief Medical Officer (Age 68)
  • Mr. Salim Hamir F.C.A., Company Sec.

What other stocks do shareholders of Renalytix own?

What is Renalytix's stock symbol?

Renalytix trades on the London Stock Exchange (LON) under the ticker symbol "RENX."

How do I buy shares of Renalytix?

Shares of RENX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Renalytix's stock price today?

One share of RENX stock can currently be purchased for approximately GBX 117.50.

How much money does Renalytix make?

Renalytix (LON:RENX) has a market capitalization of £87.84 million and generates £2.42 million in revenue each year.

How many employees does Renalytix have?

Renalytix employs 51 workers across the globe.

How can I contact Renalytix?

The official website for Renalytix is www.renalytixai.com. The company can be reached via phone at 44 20 3139 2910.

This page (LON:RENX) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.